Daily Respiratory Research Analysis
Analyzed 319 papers and selected 3 impactful papers.
Summary
Analyzed 319 papers and selected 3 impactful articles.
Selected Articles
1. Phase 2a Randomized Placebo-Controlled Human Challenge Trial of the RSV L-Protein Inhibitor S-337395 for Respiratory Syncytial Virus Infection.
In a randomized, double-blind human challenge study, oral S-337395 reduced RSV viral load and symptoms with a clear dose-response, particularly at 30 mg and 300 mg, and was well tolerated. These findings support RSV L-protein inhibition as a promising antiviral strategy.
Impact: First proof-of-concept randomized human challenge demonstrating robust antiviral activity of an oral RSV polymerase (L) inhibitor with symptom benefit.
Clinical Implications: Provides clinical rationale to advance S-337395 to larger patient trials and informs dose selection; supports development of oral RSV antivirals to complement or substitute monoclonal/prefusion F strategies.
Key Findings
- S-337395 30 mg and 300 mg reduced qRT-PCR viral load AUC by 64.87% and 88.94%, respectively (both p<0.05).
- Viral culture AUC decreased by 72.32% (30 mg) and 86.17% (300 mg) versus placebo (both p<0.05).
- Total symptom score AUC was 78.15% lower with 300 mg (p<0.05); safety profile showed no concerns.
Methodological Strengths
- Randomized, double-blind, placebo-controlled human challenge design with dose-ranging.
- Dual virologic endpoints (qRT-PCR and culture) plus symptom outcomes.
Limitations
- Single-center human challenge in healthy adults limits generalizability to high-risk patient populations.
- Short follow-up and surrogate endpoints; clinical outcomes in natural infection not assessed.
Future Directions: Proceed to multi-center patient trials (infants, older adults, comorbidities), evaluate time-to-recovery and hospitalization endpoints, and explore resistance and combination strategies.
BACKGROUND: S-337395 is a novel inhibitor of the respiratory syncytial virus (RSV) L-protein, and a potential oral antiviral against RSV. This phase 2a, randomized, double-blind, placebo-controlled, single-center, proof-of-concept trial conducted in the United Kingdom (April-October 2024) evaluated the efficacy, safety, and dose-response relationship of S-337395 against RSV infection in a human challenge model. METHODS: Healthy adults aged 18-55 years meeting predefined eligibility criteria were inoculated with RSV-A Memphis 37b on Day 0. Nasal washes were collected for quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) assessment twice daily on Days 2-12 and once on Day 13. Participants were randomized 5:13:13:13:13 to receive S-337395 (1, 10, 30, or 300 mg) or placebo, once daily for 5 days upon evidence of infection. Efficacy analyses were conducted in participants with confirmed RSV infection in intent-to-treat infected (ITT-I) set. Safety was assessed in all randomized participants. Dose-response was evaluated across a wide dose range (1-300 mg). RESULTS: Of 114 randomized participants, 60 comprised the ITT-I set. Covariate-adjusted mean viral load area under the curve (VL-AUC) was significantly lower in the 30-mg and 300-mg groups by qRT-PCR (64.87% and 88.94% reductions, respectively, both p<0.05) and by viral culture assay (72.32% and 86.17% reductions, respectively, both p<0.05). Total Symptom Score AUC was 78.15% lower in the 300-mg group (p<0.05). S-337395 was well-tolerated without any safety concerns. CONCLUSIONS: S-337395 significantly reduced viral load, viral titer, and symptoms, and was well-tolerated in this human challenge study.
2. Airway Occlusions to Measure Inspiratory Effort, Respiratory Drive, and Lung Mechanics During Noninvasive Ventilation.
In a multicenter physiologic study of 60 hypoxemic patients, end-expiratory occlusion pressure (Pocc) during NIV reliably estimated inspiratory effort (ΔPes) and dynamic transpulmonary driving pressure (ΔPL,dyn) across interfaces using interface-specific conversion factors. Pocc-derived estimates identified high effort with excellent discrimination and were associated with subsequent reintubation risk, whereas ventilator P0.1 and plateau pressure were less reliable.
Impact: Provides a practical, bedside-ready method to quantify inspiratory effort and lung stress during NIV without esophageal balloons, enabling safer titration and risk stratification.
Clinical Implications: Use Pocc-derived estimates to titrate pressure support and PEEP during NIV, identify patients with excessive effort, and anticipate reintubation risk; avoid overreliance on ventilator P0.1 and plateau pressure during NIV.
Key Findings
- Pocc was measurable in all NIV patients; interface-specific K factors (0.71 oro-nasal, 0.80 full-face) enabled accurate prediction of ΔPes and ΔPL,dyn.
- Predicted ΔPes identified high inspiratory effort (AUC 0.98 oro-nasal, 0.97 full-face) and higher predicted effort and lung stress correlated with reintubation.
- Ventilator P0.1 and plateau pressure were unreliable during NIV (plateau unstable in 78–90%).
Methodological Strengths
- Multicenter design with within-patient randomized interface sessions and gold-standard esophageal manometry calibration
- Derivation/validation with cross-validation and quantitative agreement analyses (bias and limits of agreement)
Limitations
- Physiologic endpoints; not a randomized outcomes trial testing protocolized Pocc-guided management
- Generalizability limited to hypoxemic, recently extubated patients; plateau pressure instability limits its utility
Future Directions: Prospective interventional trials testing Pocc-guided NIV titration on clinical outcomes and external validation across broader patient populations (e.g., de novo hypoxemic respiratory failure, COPD exacerbations).
RATIONALE: In intubated patients, occlusion maneuvers allow non-invasive assessment of inspiratory effort, respiratory drive and lung mechanics. OBJECTIVES: To assess the feasibility of occlusion maneuvers during noninvasive ventilation (NIV). METHODS: In this multicenter study, 60 hypoxemic patients underwent two randomized 1-hour NIV sessions with oro-nasal and full-face masks after extubation. End-expiratory and end-inspiratory occlusions measured expiratory occlusion pressure (Pocc), 100-ms airway-pressure drop (P0.1), and plateau pressure. Esophageal manometry, calibrated before extubation, provided reference values for inspiratory effort, assessed as esophageal pressure swing (ΔPes), and dynamic transpulmonary driving pressure (ΔPL,dyn = pressure support - ΔPes). Interface-specific conversion factors (K) translating Pocc into predicted ΔPes (K × Pocc) and predicted ΔPL,dyn (pressure support - predicted ΔPes) were derived through 100-interaction cross-validation (20-patient derivation set, 40-patient validation set). MAIN RESULTS: Pocc was measurable in all patients. Mean K was 0.71 with the oro-nasal mask and 0.80 with the full-face mask. Predicted ΔPes agreed with observed ΔPes (oro-nasal bias -0.41 cm H2O, 95% limits of agreement -2.3 to 1.5; full-face 0.09, -2.9 to 3.1), and predicted ΔPL,dyn agreed with observed ΔPL,dyn (oro-nasal bias 0.03, -2.9 to 2.9; full-face -0.04, -4.3 to 4.2). Predicted ΔPes identified observed ΔPes ≤ -10 cm H2O, with areas under the receiver-operating-characteristic curve of 0.98 (oro-nasal) and 0.97 (full-face). Ventilator-derived P0.1 did not precisely quantify respiratory drive, but values >2.7 cm H2O with the oro-nasal mask and >3 cm H2O with the full-face mask identified high drive with specificity >90%. Plateau pressure was unstable in 78% (oro-nasal) and 90% (full-face) of patients. More negative predicted ΔPes, higher predicted ΔPL,dyn, and lower predicted lung compliance (expiratory tidal volume/predicted ΔPL,dyn) were associated with subsequent re-intubation. CONCLUSION: During NIV, Pocc-derived parameters provide non-invasive estimates of inspiratory effort, lung stress and mechanics, whereas ventilator P0.1 and plateau pressure are less reliable.
3. A nationwide analysis of hospitalised patients with lower respiratory infections in China: life-stage-specific pathogen spectra, co-detection networks, and sex disparities.
Using tNGS on 695,142 BALF samples from 4,758 hospitals, investigators mapped life-stage-specific pathogen spectra, identified 124 coinfecting pathogen pairs forming three dominant co-detection networks (capturing 79.03% of co-detections), and revealed notable sex disparities with certain bacteria and fungi more frequent in males and greater male representation among severe LRI at ages 0–4 and ≥35.
Impact: Unprecedented national-scale, life-stage-resolved pathogen mapping with co-detection networks directly informs diagnostic panel design, empiric therapy, and vaccination strategies.
Clinical Implications: Adopt age- and sex-stratified diagnostic panels and empiric pathways for hospitalized LRTIs; anticipate frequent coinfections within the three dominant networks; tailor prevention (e.g., vaccination) to life-stage risks.
Key Findings
- Analyzed 695,142 BALF samples from 4,758 hospitals (Jan 2022–May 2025) for 28 respiratory pathogens via tNGS.
- Identified 124 coinfecting pathogen pairs and three co-detection networks encompassing 79.03% of observed co-detections.
- Observed sex disparities: pathogens such as KPN, PJ, and ABA were more frequent in males; severe LRI hospitalization was more common in males aged 0–4 and ≥35.
Methodological Strengths
- Extraordinary nationwide scale across thousands of hospitals with standardized tNGS on BALF
- Life-stage stratification and network-level analysis of co-detections enabling actionable insights
Limitations
- BALF-based sampling may introduce selection bias toward more severe or procedurally accessible cases
- Limited linkage to patient-level clinical outcomes and lack of longitudinal follow-up
Future Directions: Integrate patient-level outcomes, antimicrobial exposure, and vaccination data; validate co-detection networks prospectively; translate findings into life-stage-specific diagnostic panels and stewardship algorithms.
Lower respiratory infections (LRIs) are the foremost cause of infection-related mortality worldwide. However, the specific aetiological agents responsible for high hospitalisation rates and elevated coinfection risks across different populations have not been systematically investigated, primarily constrained by clinical practices that often target few pathogens and employ inconsistent testing methods across hospitals. Here, we collected 695,142 bronchoalveolar lavage fluid (BALF) samples from patients hospitalised with LRIs across 4758 hospitals of Chinese mainland between January 2022 and May 2025 and analysed 28 common respiratory pathogens using targeted next-generation sequencing (tNGS). Based on the real-world pathogen spectrum, we stratified the hospitalised patients undergoing BALF sampling into eight distinct age groups, corresponding to eight life-stages, and established life-stage-specific patterns of pathogen distribution. Subsequently, we identified 124 coinfecting pathogen pairs and three characteristic co-detection networks. 79.03% of observed co-detections occurred within these networks. Furthermore, our analysis revealed that bacteria and fungi such as KPN, PJ, and ABA were more frequently detected in hospitalised male patients, which indicates sex-specific differences in detection patterns. We also observed that males aged 0-4 years and 35+ years were more frequently represented among hospitalised patients with severe LRIs. These findings may inform age- and sex- stratified infectious disease prevention, control, and clinical management. Specifically, they may support public health practitioners in optimizing vaccination strategies; assist diagnostic developers in creating life-stage-specific diagnostic panels that prioritize commonly detected pathogens; and aid clinicians in assessing patterns of hospitalisation and co-detection based on nationwide data from BALF-sampled hospitalised LRI cases.